Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-1300 in Graves' Disease
NCT07901244Phase 3Not yet recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 3, open-label, single-arm trial of BHV-1300 in Graves' disease, sponsored by Biohaven Ltd. Primary endpoints: Frequency of Serious Adverse Events, Severe AEs, AEs Leading to Discontinuation, or Deaths at 52 weeks and Frequency of Clinically Significant Laboratory Abnormalities at 52 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BHV-1300
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07901244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901244.